These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36483622)

  • 1. Antiplatelet efficacy of ticagrelor versus clopidogrel in Mediterranean patients with diabetes mellitus and chronic coronary syndromes: A crossover pharmacodynamic investigation.
    Marcano AL; Gracida M; Roura G; Gomez-Lara J; Romaguera R; Teruel L; Fuentes L; Muntané-Carol G; Meroño O; Sosa SG; Gómez-Hospital JA; Comin-Colet J; Ferreiro JL
    Front Cardiovasc Med; 2022; 9():1057331. PubMed ID: 36483622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
    Franchi F; Rollini F; Aggarwal N; Hu J; Kureti M; Durairaj A; Duarte VE; Cho JR; Been L; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2016 Sep; 134(11):780-92. PubMed ID: 27559041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
    Galli M; Rollini F; Been L; Zenni MM; Angiolillo DJ; Franchi F
    J Thromb Thrombolysis; 2022 Oct; 54(3):461-469. PubMed ID: 36048358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
    Sweeny JM; Angiolillo DJ; Franchi F; Rollini F; Waksman R; Raveendran G; Dangas G; Khan ND; Carlson GF; Zhao Y; Teng R; Mehran R
    J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28356282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.
    Rollini F; Franchi F; Cho JR; DeGroat C; Bhatti M; Muniz-Lozano A; Singh K; Ferrante E; Wilson RE; Dunn EC; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    Eur Heart J; 2016 Sep; 37(35):2722-30. PubMed ID: 26848148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.
    Franchi F; Rollini F; Been L; Maaliki N; Abou Jaoude P; Rivas A; Zhou X; Jia S; Briceno M; Lee CH; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Eur Heart J Cardiovasc Pharmacother; 2022 Aug; 8(5):452-461. PubMed ID: 34114623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.
    Franchi F; Rollini F; Rivas Rios J; Rivas A; Agarwal M; Kureti M; Nagaraju D; Wali M; Shaikh Z; Briceno M; Nawaz A; Moon JY; Been L; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2018 Jun; 137(23):2450-2462. PubMed ID: 29526833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
    Storey RF; Angiolillo DJ; Patil SB; Desai B; Ecob R; Husted S; Emanuelsson H; Cannon CP; Becker RC; Wallentin L
    J Am Coll Cardiol; 2010 Oct; 56(18):1456-62. PubMed ID: 20832963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
    Angiolillo DJ; Badimon JJ; Saucedo JF; Frelinger AL; Michelson AD; Jakubowski JA; Zhu B; Ojeh CK; Baker BA; Effron MB
    Eur Heart J; 2011 Apr; 32(7):838-46. PubMed ID: 21252171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
    Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
    J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects.
    Guo LZ; Kim MH; Jin CD; Lee JY; Yi SJ; Park MK; Cho YR; Park TH
    Platelets; 2015; 26(6):563-9. PubMed ID: 25275429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease.
    Orme RC; Parker WAE; Thomas MR; Judge HM; Baster K; Sumaya W; Morgan KP; McMellon HC; Richardson JD; Grech ED; Wheeldon NM; Hall IR; Iqbal J; Barmby D; Gunn JP; Storey RF
    Circulation; 2018 Sep; 138(13):1290-1300. PubMed ID: 29930021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease.
    Price MJ; Clavijo L; Angiolillo DJ; Carlson G; Caplan R; Teng R; Maya J
    J Thromb Thrombolysis; 2015 Jan; 39(1):8-14. PubMed ID: 25305090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High and low on-treatment platelet reactivity to P2Y
    Ferreiro JL; Vivas D; De La Hera JM; Marcano AL; Lugo LM; Gómez-Polo JC; Silva I; Tello-Montoliu A; Marín F; Roldán I
    Thromb Res; 2019 Mar; 175():95-101. PubMed ID: 30738371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study.
    Jeong KH; Cho JH; Woo JS; Kim JB; Kim WS; Lee TW; Kim KS; Ihm CG; Kim W
    Am J Kidney Dis; 2015 Jun; 65(6):916-24. PubMed ID: 25622774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus.
    Clavijo LC; Maya J; Carlson G; Angiolillo DJ; Teng R; Caplan R; Price MJ
    Cardiovasc Revasc Med; 2015 Dec; 16(8):450-4. PubMed ID: 26440227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
    Cho JR; Rollini F; Franchi F; DeGroat C; Bhatti M; Dunn EC; Ferrante E; Muniz-Lozano A; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1075-1083. PubMed ID: 26117466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study.
    Waksman R; Maya J; Angiolillo DJ; Carlson GF; Teng R; Caplan RJ; Ferdinand KC
    Circ Cardiovasc Interv; 2015 Jul; 8(7):e002232. PubMed ID: 26152562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, pharmacodynamic comparison.
    Alexopoulos D; Kontoprias K; Gkizas V; Karanikas S; Ziakas A; Barampoutis N; Tsigkas G; Koutsogiannis N; Davlouros P; Patsilinakos S; Karvounis H; Hahalis G; Xanthopoulou I
    Platelets; 2016 Jul; 27(5):420-6. PubMed ID: 26763727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.
    Shang LL; Guo DD; Zhao HY; Quan AJ; Cao PG
    J Clin Pharm Ther; 2018 Jun; 43(3):342-347. PubMed ID: 29150850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.